Opioids News and Research

RSS

An opioid is a chemical that works by binding to opioid receptors, which are found principally in the central nervous system and the gastrointestinal tract. The receptors in these two organ systems mediate both the beneficial effects and the side effects of opioids.

Real-time prescription system reduces inappropriate prescribing of medications

A centralized prescription network providing real-time information to pharmacists in British Columbia, Canada, resulted in dramatic reductions in inappropriate prescriptions for opioid analgesics and benzodiazepines, widely used and potentially addictive drugs. The findings are reported in a study in CMAJ (Canadian Medical Association Journal).

5 Sep 2012

Data from ESTEVE’s S1RA E-52862 Phase I trial programme on pain

ESTEVE announces the recent publication of data from the Phase I clinical trial programme of a novel, highly potent and selective, once-daily, S1RA E-52862, developed by the ESTEVE R&D team, in the British Journal of Clinical Pharmacology.

4 Sep 2012

Incentives can help promote drug abstinence among pregnant women with heroin or cocaine addiction

A "contingency management" approach—offering incentives for negative drug tests—can help promote drug abstinence among pregnant women with heroin or cocaine addiction, reports a study in the September Addictive Disorders & Their Treatment. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

1 Sep 2012

Non-pain-related factors predict long-term opioid use after surgery

Non-pain-related factors—including previous use of pain medications, high perceived risk of addiction, and symptoms of depression—increase the risk of continuing to use strong pain-relieving drugs several months after surgery, reports a study in the September issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

31 Aug 2012

Chronic nerve pain: an interview with Professor Sally Lawson

Chronic nerve pain results from pathological changes within a nerve that appear to be self-sustaining and thus the pain continues for a long time.

30 Aug 2012

Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain today announced that it has initiated enrollment in its Phase 3 clinical study for Oxycodone DETERx (COL-003).

30 Aug 2012

Tris Pharma joins Perrigo to launch first ever store brand ER liquid cough/cold product

Perrigo Company and Tris Pharma, Inc. today announced the commercial launch of a major new store brand product. The new product is equivalent to Delsym extended–release oral liquid suspension containing dextromethorphan polistirex and will be marketed under major U.S. retailer and wholesalers' store brands or own label brands.

27 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) filed by Mallinckrodt Inc., a subsidiary of Covidien plc, for the 32 mg dose strength of EXALGO (hydromorphone HCl) Extended-Release Tablets (CII), for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Electronic PMP use may have impact on demand for drug treatment programs, painkiller abuse

A Rhode Island Hospital researcher has found that the use of electronic prescription drug monitoring programs (PMPs) may have a significant impact on the demand for drug treatment programs and how prescribers detect and respond to abuse of painkillers.

17 Aug 2012

ACOEM integrates U.S. FDA's National Drug Code data into APG-I

The American College of Occupational and Environmental Medicine (ACOEM) has integrated the U.S. Federal Drug Administration's National Drug Code (NDC) data into APG-I, the College's on-line Occupational Medicine Practice Guidelines data base.

17 Aug 2012

Addiction to morphine and heroin can be blocked via brain's immune response

In a major breakthrough, an international team of scientists has proven that addiction to morphine and heroin can be blocked, while at the same time increasing pain relief.

15 Aug 2012

Risk model predicts illness after ambulatory surgery

A marked proportion of patients undergoing ambulatory surgery suffer postdischarge nausea and vomiting, say US scientists who have developed a simplified risk score to identify patients who may benefit from long-acting prophylactic therapy.

9 Aug 2012

Combination of two existing pharmaceutical drugs shows promise against cocaine addiction

A fine-tuned combination of two existing pharmaceutical drugs has shown promise as a potential new therapy for people addicted to cocaine—a therapy that would reduce their craving for the drug and blunt their symptoms of withdrawal.

9 Aug 2012

BMC to implement and evaluate opioid risk reduction model in primary care settings

Researchers at Boston Medical Center (BMC) have received a $2.67 million grant from the National Institute on Drug Abuse (NIDA) to implement and evaluate a new model of care in primary care settings aimed at decreasing the misuse of and addiction to opioids among patients with chronic pain.

2 Aug 2012

New FDA risk management plan aims to reduce opioid abuse in the U.S.

A new risk management plan from the U.S. Food and Drug Administration to help clinicians properly prescribe drugs with addiction potential aims to help reduce the growing epidemic of opioid abuse in the United States.

2 Aug 2012

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

31 Jul 2012

Orthognathic surgery requires a balancing act in anesthetic technique

Orthognathic surgery, affecting the jaws and face, requires a balancing act in anesthetic technique. Limiting blood loss, avoiding respiratory depression, and averting postoperative nausea and vomiting lead to optimum patient outcomes. The use of the drugs propofol and remifentanil are increasing because they can meet these needs; however, patients may subsequently experience more postoperative pain.

27 Jul 2012

Takeda, Sucampo file AMITIZA sNDA with FDA for treatment of opioid-induced constipation

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A. Inc. today announced the filing of a supplemental new drug application (sNDA) with the US Food and Drug Administration (FDA) seeking approval for a new indication for AMITIZA (lubiprostone) for the treatment of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain.

26 Jul 2012

BJP publishes data from ESTEVE's E-52862 preclinical studies on pain

ESTEVE announces the recent publication in the British Journal of Pharmacology of important preclinical data that furthers understanding of its highly potent and selective, once-daily, S1R antagonist E-52862, developed by the ESTEVE Research and Development (R&D) team.

18 Jul 2012

Opioids News and Research

Further Reading

Real-time prescription system reduces inappropriate prescribing of medications

Data from ESTEVE’s S1RA E-52862 Phase I trial programme on pain

Incentives can help promote drug abstinence among pregnant women with heroin or cocaine addiction

Non-pain-related factors predict long-term opioid use after surgery

Chronic nerve pain: an interview with Professor Sally Lawson

Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain

Tris Pharma joins Perrigo to launch first ever store brand ER liquid cough/cold product

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Electronic PMP use may have impact on demand for drug treatment programs, painkiller abuse

ACOEM integrates U.S. FDA's National Drug Code data into APG-I

Addiction to morphine and heroin can be blocked via brain's immune response

Risk model predicts illness after ambulatory surgery

Combination of two existing pharmaceutical drugs shows promise against cocaine addiction

BMC to implement and evaluate opioid risk reduction model in primary care settings

New FDA risk management plan aims to reduce opioid abuse in the U.S.

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Orthognathic surgery requires a balancing act in anesthetic technique

Takeda, Sucampo file AMITIZA sNDA with FDA for treatment of opioid-induced constipation

BJP publishes data from ESTEVE's E-52862 preclinical studies on pain

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News